Surgical Infection Rates With Adjunct Vancomycin Compared to Standard Peri-Operative IV Antibiotics
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49503
- Recruiting
- Spectrum Health Hospitals
-
Contact:
- Nichole Rodrique
- Phone Number: 616-258-3886
- Email: Nichole.Rodrique@spectrumhealth.org
-
Principal Investigator:
- Jason Squires, DO
-
Sub-Investigator:
- Sanja Patra, MD
-
Sub-Investigator:
- Marilyn Gates, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All adult, 18 years or greater undergoing posterior approach spinal surgery
Exclusion Criteria:
- Prisoner, pregnant women, patient under the age of 18, those of diminished decision making capacity.
- patients with known reaction to Vancomycin.
- patients having surgery specifically for spine infection
- patients having ADCF or ALIF
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Vancomycin
Patient will receive Vancomycin powder to the incision just before skin closure
|
Patient will be randomized to either vancomycin or no vancomycin.
This treatment will take place prior to the closure of the incision from back surgery.
|
|
No Intervention: no vancomycin
Patient will be randomized to either vancomycin powder or no vancomycin powder.
This arm the patient will not have the powder placed in the incision before skin closure.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Surgical wound infection rate, both deep and superficial infections
Time Frame: 12 weeks post surgery
|
12 weeks post surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Post-operative rate of MRSA infections.
Time Frame: 12 weeks post surgery
|
12 weeks post surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jason Squires, DO, Spectrum Health Hospitals
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2012-166
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.